CC BY
31Expression levels of the microRNA maturing microprocessor complex components; Drosha, Dicer, and DGCR8 in PBMCs from ankylosing spondylitis patients
Zeinab Tabrizi, Reza Mansouri, Saeed Aslani, Ahmad Reza Jamshidi, Mahdi Mahmoudi
Mediterr J Rheumatol 2017; 28(2):80-5
(iij^ AN EDITION OF GREEK RHEUMATOLOGY SOCIETY AND PROFESSIONAL ASSOCIATION OF RHEUMATOLOGISTS e-ISSN: 2529-198X
mediterranean journal of RHEUMATOLOGY
(0
thttp^^W^jitieum^^ June 2017 | Volume 28 | Issue 2
E-ISSN: 2529-198X
MEDITERRANEAN JOURNAL OF RHEUMATOLOGY June 2017 | Volume 28 | Issue 2
mediterranean journal
of RHEUMATOLOGY
28 2
2017
© Tabrizi Z, Mansouri R, Aslani A, Jamshidi A R, Mahmoudi M
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International L
©CD®
ORIGINAL PAPER
Expression levels of the microRNA maturing microprocessor complex components; Drosha, Dicer, and DGCR8 in PBMCs from ankylosing spondylitis patients
Zeinab Tabrizi1,2, Reza Mansouri2, Saeed Aslani1, Ahmad Reza Jamshidi1, Mahdi Mahmoudi1
Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran, 2Immunology Department, Shahid Sadoughi University of Medical Sciences (International Campus), Yazd, Iran
ABSTRACT
Objective/Aim: Two major enzymes in the microRNA maturation process, Dicer and Drosha, as well as DGCR8, the assistant of Drosha, function in the microprocessor complex. In this survey, the mRNA expression profiles of Drosha, Dicer, and DGCR8 in peripheral blood mononuclear cells (PBMCs) from ankylosing spondylitis (AS) patients and healthy controls were measured. Methods: Forty patients with AS and 40 age and gender matched healthy individuals were included in the study. PBMCs were separated, total RNA content of the cells was isolated, and first strand cDNA was synthesized. Quantitative analysis was performed through real-time PCR using the SYBR Green gene expression master mix. Results: AS cases expressed the Drosha mRNA almost equal to that of healthy controls (Fold Change= -0.94; P= 0.200). However, both Dicer and DGCR8 mRNA expressions were downregulated in patients relative to healthy subjects (Fold Change= -0.54 and -0.60; P= 0.002 and 0.004, respectively). Conclusion: Our results suggest that downregulation of miRNA maturation components, namely Dicer and DGCR8 may be contributing in the pathogenesis procedure of AS.
Mediterr J Rheumatol 2017;28(2):80-5 https://doi.org/10.31138/mjr282.80
Article Submitted 28/12/2016; Revised Form 16/03/2017; Article Accepted 09/04/2017
Keywords: Drosha, Dicer, DGCR8, Ankylosing spondylitis.
INTRODUCTION
MicroRNAs (miRNAs), a group of non-coding RNAs, are post-transcriptional regulators which are involved in many biological procedures, including development, differentiation, proliferation, and apoptosis.1 They are substantial gene expression regulators that control both physiological and pathological processes such as cancer, autoimmune diseases, and chronic inflammatory conditions.2 miRNAs synthesis initiates by transcribing miRNA genes into primary miRNA (pri-miRNA) transcripts through ei-
ther RNA polymerase II or RNA polymerase III.3 As the hairpins are formed in pri-miRNA, it is identified by a nuclear protein known as DiGeorge syndrome critical region gene 8 (DGCR8 or Pasha) which is linked with Drosha protein, an enzyme that cuts RNA to develop the microprocessor complex.4 In this complex, the catalytic RNase III domain of Drosha, which is oriented by DGCR8, releases the hairpins from pri-miRNAs by cleaving approximately eleven nucleotides from the hairpin base to produce pre-miRNAs.5 After that, the pre-miR-NA with 70-90 nucleotide length is transported to the cytoplasm through exportin-5 for further processing. In the cytoplasm, Dicer, which holds RNase III enzyme activity, processes the pre-miRNA to create mature miRNA with desired function.6 Therefore, it seems that the role of
Corresponding author:
Mahdi Mahmoudi, PhD Rheumatology Research Center Shariati Hospital, Kargar Ave. Tehran 14117-13137, Iran Tel/Fax: +98-21-8822-0067 E-mail: [email protected]
80 Cite this article as: Tabrizi Z, Mansouri R, Aslani A, Jamshidi A R, Mahmoudi M. Expression levels of the microRNA maturing microprocessor complex components; Drosha, Dicer, and DGCR8 in PBMCs from ankylosing spondylitis patients. Mediterr J Rheumatol 2017;28(2):80-5.
Drosha, Dicer, and DGCR8 as the major miRNA biogenesis constituents is inevitable.
Ankylosing spondylitis (AS) is a type of arthritis with chronic inflammation in the spine and sacroiliac joints, that is commonly defined by pain and stiffness at the spine and other peripheral joints.7-9 Given that AS is a multifactorial disease, it is a consensus nowadays that both environmental factors and genetics are involved in the initiation and perpetuation of the disease.10,11 However, the exact etiology underlying the pathogenesis of AS remains obscure. Human leukocyte antigen (HLA)-B27 has been identified to be vigorously associated with AS but accounts for only a part of the overall risk for it, implying to the involvement of other genes in the development of the disease.12-15
The contributory role of miRNAs to the pathological conditions involving the immune system, like autoimmunity has been addressed by numerous studies. Even though downregulation or upregulation of several miRNAs has been shown in this disease, their involvement in the etio-pathology of AS has not been surveyed extensively.16 Three miRNAs, miR-16, miR-221, and let-7i, were upreg-ulated in T cells obtained from AS patients. Upregulation of reported miRNAs were found to be correlated positively with the disease activity.17 Moreover, miR-29 has been known as a useful diagnostic marker for new bone formation in AS and might be a promising therapeutic tool.18 Recently, studies have concentrated on the involvement of miRNAs in AS disease, suggesting that miRNAs may be involved in the development of AS. Considering the controversial expression level of miRNAs in peripheral blood cells of AS patients, and noting that expression levels of Drosha, Dicer, and DGCR8 genes have not been investigated in AS, we decided to measure the transcript level of these three primary components of miRNA biosynthesis machinery in AS patients.
MATERIALS AND METHODS Study subjects
The patients were recruited from Rheumatology Research Center, Shariati Hospital, Tehran, Iran, and diagnosis of AS was carried out according to the modified New York criteria.19 Intensity of the disease and functional limitations were measured by bath ankylosing spondy-litis disease activity index (BASDAI),20,21 bath ankylosing spondylitis functional index (BASFI),21,22 and bath ankylosing spondylitis metrology index (BASMI).20,21 Forty AS patients and 40 healthy controls (age and gender matched) were included in the study. Healthy control volunteers did not have autoimmune disease neither themselves nor their immediate family members. Patients had not received immunomodulatory therapy for at least 3 months before they were entered in the study. The Human Research Ethics Committees from Tehran University of Medical Sciences sanctioned this study. All the par-
ticipants signed the informed consent form. From each subject, 10 ml of blood was obtained in EDTA-anticoag-ulated and ESR blood collection test tubes by venipunc-ture.
PBMC isolation and RNA extraction
For isolating the PBMCs from peripheral blood, the Fi-coll-Hypaque density gradient centrifugation approach was exploited. High Pure RNA Isolation Kit (Roche, Germany), according to manufacturer's manuals, was used for total RNA extraction. To evaluate the yield and purity of extracted RNA, NanoDrop spectrophotometer (2000c, Thermo Fisher Scientific, USA) at 260/280 nm absorbance was applied.
cDNA synthesis
After RNA extraction, synthesis of first strand complementary DNA (cDNA) was done using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany). In brief, to synthesize cDNA in a final volume of 20 pl, 1 |jg of RNA was added in a micro tube, and mixed with 2 pl of primer (random hexamer) and adequate RNase-free H2O; and then incubation was done at 65°C for 10 minutes. Following micro tubes were chilled on ice, and RNase inhibitor 0.5 pl, reaction buffer 4 pl, dNTP mix 2 pl, and reverse transcriptase enzyme 0.5 pl were added to each micro tube. Afterwards, each tube was incubated at 25°C for 10 minutes and followed by 50°C for 60 minutes; and the reaction was finished after heating at 85°C for 5 minutes.
Quantitative real-time polymerase chain reaction
Primers used in this study were adopted from the previously published works by Sand et al, in which the transcript levels of Drosha, Dicer, DGCR8, and RNA induced silencing complex (RISC) components in epithelial skin cancer were determined.23,24 In order to evaluate the specificity, primers (Drosha, Dicer, DGCR8, and RPL38 as a housekeeping gene) were checked using the Basic Local Alignment Search Tool (BLAST) on the NCBI website.25 Refer to Table 1 for the primer's features with more details. Quantitative analysis was carried out by real-time PCR using the SYBR Green gene expression master mix (Takara Bio, Inc.) and StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA, USA). Each reaction mixture contained a total volume of 20 pl (master mix 10 pl, cDNA 2 pl [5ng/ml], forward and reverse primer 1 pl of each, and H2O 6 pl). The conditions of quantitative real-time PCR were: first, 95°C for 30 seconds, 40 cycles in 95°C for 15 seconds, and finally 60°C for 1 minute. To calculate the relative gene expression, comparative C method was used, as previously elucidated by Livak and Schmittgen.26 Relative transcript levels of the target mRNAs were normalized versus to the corresponding housekeeping gene, namely RPL38 mRNA transcript level. Ultimately, the rel-
mediterranean journal
of RHEUMATOLOGY
28 2
2017
Table 1. Primers used for real-time gene expression of Drosha, Dicer, and DGCR8.
Target genes Sequence Amplicon size (bp) Tm (°C)
Drosha F 5'-CATGTCACAGAATGTCGTTCCA-3' 115 58.4
Drosha R 5'-GGGTGAAGCAGCCTCAGATTT-3' 115 59.8
Dicer F 5'-IIAACCIIIIGGIGIIIGAIGAGIGI-3' 94 58.5
Dicer R 5'-GGACATGATGGACAA TTTTCACA-3' 94 57.1
DGCR8 F 5'-GCAAGATGCACCCACAAAGA-3' 93 57.3
DGCR8 R 5'-TTGAGGACACGCTGCATGTAC-3' 93 59.8
RPL38F 5'-TCACTGACAAAGAGAAGGCAGAGA-3' 88 61
RPL38 R 5'-TCAGTGTGTCTGGTTCATTTCAGTT-3' 88 59.7
ative mRNA expression level for each sample was calculated by the equation below, for simplicity of visualization: relative mRNA expression= (2-ACt) x 100.
Statistical Analysis
Analysis of data was fulfilled via SPSS software version 21 (SPSS, Chicago, IL, USA). To assess the normal distribution of the scale variables, the Kolmogorov-Smirnov test was used. The independent sample f-test was used to compare groups with continues variables. The Graph-Pad Prism version 5.00 software (GraphPad Software, La Jolla California USA, www.graphpad.com) was applied to draw the graphs. Scale data were expressed as mean ± standard deviation (SD). A P-value < 0.05 was set to be statistically significant.
RESULTS
Study population was comprised of 40 AS patients (29 males and 11 females) with the mean age of 39.8 ± 11.49 and 40 healthy individuals (30 males and 10 females) with the mean age of 38 ± 9.39. ESR level of the patients and healthy controls were 35 ± 18.24 and 4.4 ± 3.82, respectively. BASDAI, BASFI, and BASMI scores of the AS patients were 4.44 ± 2.13, 2.9 ± 2.08, and 4.56 ± 1.9, respectively (Table 2).
We did not observe statistically significant difference (Fold change= -0.94; P= 0.200) in the expression level of Drosha between AS patients and healthy control groups (Table 3, Figure 1). However, PBMCs from AS patients expressed the Dicer mRNA lower (0.54 times downreg-ulated; P= 0.002) than healthy subjects (Table 3, Figure
Table 2. Demographic specifications of ankylosing spondylitis patients and healthy controls.
Property AS patients Healthy controls
Male 29 30
Female 11 10
Age 39.8 ± 11.49 38 ± 9.39
ESR 35 ± 18.24 4.4 ± 3.82
BASDAI 4.44 ± 2.13 -
BASFI 2.9 ± 2.08 -
BASMI 4.56 ± 1.9 -
Table 3. Fold changes of Drosha, Dicer, and DGCR8 expressions in patients with ankylosing spondylitis (AS) in comparison to healthy subjects (HS).
Target Gene Fold Change P-value
(AS vs. HS)
Drosha -0.94 P= 0.200
Dicer -0.54 P= 0.002
DGCR8 -0.60 P= 0.004
12-
« -IOCS
tu
o „
□ AS
□ HS
r
10-1
73
J3
Í0
£ 8-cs
I 65«
Oí
I 2"
"3 b:
o-l—----
Figure 1: Relative expression of Drosha mRNA in PBMCs from AS patients and healthy subjects is illustrated through Bar graph. AS patients did not express Drosha mRNA significantly different than control group (AS: Ankylosing spondylitis, HS: Healthy subjects).
a
0j—----
Figure 2: Relative expression of Dicer mRNA in PBMCs from AS patients and healthy subjects is illustrated through Bar graph. Expression of Dicer mRNA was significantly downregulated in AS patients compared with healthy subjects (AS: Ankylosing spondylitis, HS: Healthy subjects).
2). Also, downregulation of DGCR8 mRNA (Table 3, Figure 3) was seen in AS patients compared with healthy controls (Fold change= -0.60; P= 0.004). Given the importance of BASDAI, BASFI, and BASMI indices in screening the clinical manifestations of AS patients, we tried to evaluate the correlation of those with mRNA expression levels of target genes (Table 4). Relative expression level of Drosha did not correlate with BASDAI (P= 0.167, r= -0.203), BASFI (P= 0.318, r= -0.147), and BASMI values (P= 0.883, r= -0.022) of AS patients. As such, none of the BASDAI (P= 0.447, r= 0.122), BASFI (P= 0.596, r= -0.085), and BASMI (P= 0.156, r= -0.226) scores of AS patients correlated with relative expression level of Dicer. Furthermore, relative expression of DGCR8 did not show correlation with BASDAI (P= 0.512, r= 0.110), BASFI (P= 0.954, r= -0.010), and BASMI (P= 0.341, r= 0.159) scores of AS patients.
DISCUSSION
Application of epigenetics to autoimmune diseases, and especially AS, is in its infancy and requires new hypotheses.27 miRNAs, as a classification of epigenetics modifications, have been associated with AS by a few re-
searches and is a new trend to gain a bigger insight into the etiopathology of this disease. Hopefully, an exhaustive knowledge of miRNA implication could help to rec-
□ AS - □ HS P= 0.004*
- r 1 1
-
-
Figure 3: Relative expression of DGCR8 mRNA in PBMCs from AS patients and healthy subjects is illustrated through Bar graph. Expression of DGCR8 mRNA was significantly downregulated in AS patients compared with healthy subjects (AS: Ankylosing spondylitis, HS: Healthy subjects).
Table 4. The correlations of the expressions of Drosha, Dicer, and DGCR8 mRNAs in PBMCs from AS patients with BASDAI, BASFI, and BASMI (r; pearson's correlation coefficient).
Target genes BASDAI r (P-Value) BASFI r (P-Value) BASMI r (P-Value)
Drosha -0.203 (P= 0.167) -0.147 (P= 0.318) -0.022 (P= 0.883)
Dicer 0.122 (P= 0.447) -0.085 (P= 0.596) -0.226 (P= 0.156)
DGCR8 0.110 (P= 0.512) -0.010 (P= 0.954) 0.159 (P= 0.341)
mediterranean journal 28
of RHEUMATOLOGY 2 2017
ognize novel therapeutic targets and biomarkers for this disease.16 In recent years, dysregulation of miRNAs has been reported in AS. miR-16, miR-221, and let-7i have been observed to be upregulated in AS patients, among which let-7i and miR-221 were found to be correlated positively with Bath Ankylosing Spondylitis Radiology Index (BASRI) of lumbar spine. The study suggested that the increased expression of let-7i in AS T cells contributed to the immunopathogenesis of the disease, which is probably mediated by enhancing the Th1 (IFN-Y)-as-sociated inflammatory response.17 Moreover, let-7i was shown to regulate Dicer expression and constitute a negative feedback loop. In other words, overexpression of let-7 significantly declined the expression of Dicer at both the protein and mRNA levels. Thus, upregulation of let-7 maybe the cause of Dicer downregulation in a similar way in AS.28 As shown by Huang et al. 2014, miR-29 that directly targets the Dkk-1 mRNA, an antagonistic inhibitor of the WNT signaling pathway, had overexpression in the PBMCs from AS patients compared with rheumatoid arthritis (RA) patients as well as healthy subjects,29 suggesting that miR-29a is a useful diagnostic marker for new bone formation in AS and might be a promising therapeutic agent in the future.18 Furthermore, miR-146a can act as a regulator to prevent an overstimulated inflammatory state by impairing NF-kB activity. As a result, receptor activator of NF-kB ligand (RANKL) and pro-inflammatory cytokines contribute to the development of AS. Therefore, lower expression of miR-146a provides prolonged release of inflammatory cytokines in AS.30 As detected by Qian BP et al in 2016, the expression level of miR-155 that may serve as a novel complementary bio-marker for AS, is suggested to be associated with disease activity (BASDAI) and the severity of thoracolumbar kyphosis in AS patients.31
On the other hand, the role of miR-155 in the differentiation and function of regulatory T cells (Tregs) has been reported. In this context, several studies are indicated that conditional deletion of Dicer or Drosha in Tregs culminated in lethal inflammatory autoimmune setting, is mediated by defective development or function of Tregs. Therefore, reduced expression of Dicer and Drosha may contribute to impaired development of Tregs, implying to the role of miRNAs in the biology of Tregs and autoimmunity.32
Accordingly, investigation of miRNA processing components including Drosha, Dicer and DGCR8 is of importance to answer the questions around aberrant expression of miRNAs in AS. Several studies not only have tried to realize the expression profile of miRNA microprocessing compartments in various disorders but they also reported the dysregulated expression profiles of these three molecules in cancerous and autoimmunity conditions. Taken together, miRNAs play a role in the patho-genesis of AS.23'33-26
Here, we observed dysregulated expression level of these components in AS patients, however Drosha did not show significantly different expression level between AS patients and healthy controls. Furthermore, Dicer and DGCR8 were downregulated 0.54 and 0.60 times in patients, respectively. Moreover, none of the Drosha, Dicer, and DGCR8 expression levels correlated with disease activity indices as measured through BASDAI, BASFI, and BASMI. Even though premature, our findings favor the hypothesis that miRNAs are involved in the patho-genesis of AS by dysregulated expression levels of mi-croRNA processing enzymes.
Considering all the facts, our results, as a first time reporting the expression level of miRNA processing machinery molecules in AS, suggest that downregulation of the major miRNA machinery components, Dicer and DGCR8, provides new evidence for plausible involvement of dysregulated miRNAs in the AS development. These molecules are mandatory to be further investigated considering the other miRNA biogenesis components. Comprehensive studies may lead to introduction of new disease biomarkers for assessing possible therapeutic approaches and disease activity that may facilitate the identification of novel therapeutic targets in the future.
ACKNOWLEDGEMENTS
We are thankful of our participants for contributing to the accomplishment of this study. This study was supported by a grant from Deputy of Research, Tehran University of Medical Sciences (Grant no. 95-02-41-31183).
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
1. Meda F, Folci M, Baccarelli A, Selmi C. The epigenetics of autoimmunity. Cell Mol Immunol 2011;8:226-36.
2. Winter J, Jung S, Keller S, Gregory R I, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11:228-34.
3. Lee Y, Kim M, Han J, Yeom K H, Lee S, Baek S H, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051-60.
4. Gregory R I, Chendrimada T P, Shiekhattar R. MicroRNA biogenesis: isolation and characterization of the microprocessor complex. Methods Mol Biol 2006;342:33-47.
5. Gregory R I, Yan K-P, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004;432:235-40.
6. Kim V N. MicroRNA precursors in motion: exportin-5 mediates their nuclear export. Trends Cell Biol 2004;14:156-9.
7. Steven M M, Van Der Linden S M, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Rheumatology 1985;24:242-9.
8. Brown M A. Genetics and the pathogenesis of ankylosing spondylitis. Curr Opin Rheumatol 2009;21:318-23.
9. Jamshidi A R, Shahlaee A, Farhadi E, Fallahi S, Nicknam M H,
Bidad K, et al. Clinical characteristics and medical management of Iranian patients with ankylosing spondylitis. Mod Rheumatol 2013;24:499-504.
10. Lau C S, Burgos-Vargas R, Louthrenoo W, Mok M Y, Wordsworth P, Zeng Q Y. Features of spondyloarthritis around the world. Rheum Dis Clin North Am 1998;24:753-70.
11. Reveille J D. Recent studies on the genetic basis of ankylosing spondylitis. Curr Rheumatol Rep 2009;11:340-8.
12. Gunal E K, Sarvan F O, Kamali S, Gul A, Inanc M, Carin M, et al. Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine 2008;75:299-302.
13. Alaez C, Gazit E, Ibarrola B, Yaron M, Livneh A, Avishai O, et al. Distribution of HLA-B27 subtypes in ankylosing spondylitis in an Israeli population. Arch Med Res 2007;38:452-5.
14. Nicknam M H, Mahmoudi M, Amirzargar A A, Hakemi M G, Khosravi F, Jamshidi A R, et al. Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis. Iran J Allergy Asthma Immunol 2008;7:19-24.
15. Fallahi S, Mahmoudi M, Nicknam M H, Gharibdoost F, Farhadi E, Saei A, et al. Effect of HLA-B* 27 and its Subtypes on Clinical Manifestations and Severity of Ankylosing Spondylitis in Iranian patients. Iran J Allergy Asthma Immunol 2013;12:321.
16. Mahmoudi M, Aslani S, Nicknam M H, Karami J, Jamshidi A R. New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications. Mod Rheumatol 2016:1-12.
17. Lai N S, Yu H C, Chen H C, Yu C L, Huang H B, Lu M C. Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis. J Clin Exp Immunol 2013;173:47-57.
18. Huang J, Song G, Yin Z, Luo X, Ye Z. Elevated miR-29a expression is not correlated with disease activity index in PBMCs of patients with ankylosing spondylitis. Mod Rheumatol 2014;24:331-4.
19. Moll J, Wright V. New York clinical criteria for ankylosing spondylitis. A statistical evaluation. Ann Rheum Dis 1973;32:354.
20. Garrett S, Jenkinson T, Kennedy L G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
21. Bidad K, Fallahi S, Mahmoudi M, Jamshidi A, Farhadi E, Meysamie A, et al. Evaluation of the Iranian versions of the bath ankylosing spondylitis disease activity index (BASDAI), the bath ankylosing spondylitis functional index (BASFI) and the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Rheumatol Int 2012;32:3613-8.
22. Calin A, Garrett S, Whitelock H, Kennedy L, O'hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
23. Sand M, Gambichler T, Skrygan M, Sand D, Scola N, Altmeyer P, et al. Expression levels of the microRNA processing enzymes Drosha and dicer in epithelial skin cancer. Cancer Invest 2010;28:649-53.
24. Sand M, Skrygan M, Georgas D, Arenz C, Gambichler T, Sand D, et al. Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. Mol Carcinog 2012;51:916-22.
25. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden T L. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 2012;13:134.
26. Schmittgen T D, Livak K J. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008;3:1101-8.
27. Aslani S, Mahmoudi M, Karami J, Jamshidi A R, Malekshahi Z, Nicknam M H. Epigenetic alterations underlying autoimmune diseases. Autoimmunity 2016:1-15.
28. Tokumaru S, Suzuki M, Yamada H, Nagino M, Takahashi T. let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis 2008;29:2073-7.
29. Daoussis D, Andonopoulos A P, Editors. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum Vol. 41 No. 2. WB Saunders, 2011.
30. Xu H Y, Wang Z Y, Chen J F, Wang T Y, Wang L L, Tang L L, et al. Association between Ankylosing Spondylitis and the miR-146a and miR-499 Polymorphisms. PLoS One 2015;10:e0122055.
31. Qian B P Ji Ml, Qiu Y, Wang B, Yu Y, Shi W, et al. Identification of Serum miR-146a and miR-155 as Novel Noninvasive Complementary Biomarkers for Ankylosing Spondylitis. Spine 2016;41:735-42.
32. Raisch J, Darfeuille-Michaud A, Nguyen H T T. Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol 2013;19:2985-96.
33. Jafari N, Dogaheh H P, Bohlooli S, Oyong G G, Shirzad Z, Alibeiki F, et al. Expression levels of microRNA machinery components Drosha, Dicer and DGCR8 in human (AGS, HepG2, and KEYSE-30) cancer cell lines. Int J Clin Exp Med 2013;6:269.
34. Papachristou D J, Korpetinou A, Giannopoulou E, Antonacopoulou A G, Papadaki H, Grivas P, et al. Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas. Virchows Arch 2011;459:431-40.
35. Rahimi G, Jafari N, Khodabakhsh M, Shirzad Z, Dogaheh H P. Upregulation of microRNA processing enzymes Drosha and Dicer in gestational diabetes mellitus. Gynecol Endocrinol 2015;31:156-9.
36. Jafari N, Shaghaghi H, Mahmoodi D, Shirzad Z, Alibeiki F, Bohlooli S, et al. Overexpression of microRNA biogenesis machinery: Drosha, DGCR8 and Dicer in multiple sclerosis patients. J Clin Neurosci 2015;22:200-3.
